Sarepta Therapeutics (SRPT) – Hot FDA News
-
Sarepta Therapeutics (SRPT) Climbs 20% After Announcing U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS Indication
-
Sarepta Therapeutics' (SRPT) EMBARK Study Did Not Meet Primary Endpoint but Data Shows Robust, Statistically Significant Results
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to SRPT Stock Lookup